Cargando…
Chromogranin-A production and fragmentation in patients with Takayasu arteritis
BACKGROUND: Chromogranin-A (CgA) is a secretory protein processed into peptides that regulate angiogenesis and vascular cells activation, migration and proliferation. These processes may influence arterial inflammation and remodelling in Takayasu arteritis (TA). METHODS: Plasma levels of full-length...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987982/ https://www.ncbi.nlm.nih.gov/pubmed/27531191 http://dx.doi.org/10.1186/s13075-016-1082-2 |
_version_ | 1782448383318818816 |
---|---|
author | Tombetti, Enrico Colombo, Barbara Di Chio, Maria Chiara Sartorelli, Silvia Papa, Maurizio Salerno, Annalaura Bozzolo, Enrica Paola Tombolini, Elisabetta Benedetti, Giulia Godi, Claudia Lanzani, Chiara Rovere-Querini, Patrizia Del Maschio, Alessandro Ambrosi, Alessandro De Cobelli, Francesco Sabbadini, Maria Grazia Baldissera, Elena Corti, Angelo Manfredi, Angelo A. |
author_facet | Tombetti, Enrico Colombo, Barbara Di Chio, Maria Chiara Sartorelli, Silvia Papa, Maurizio Salerno, Annalaura Bozzolo, Enrica Paola Tombolini, Elisabetta Benedetti, Giulia Godi, Claudia Lanzani, Chiara Rovere-Querini, Patrizia Del Maschio, Alessandro Ambrosi, Alessandro De Cobelli, Francesco Sabbadini, Maria Grazia Baldissera, Elena Corti, Angelo Manfredi, Angelo A. |
author_sort | Tombetti, Enrico |
collection | PubMed |
description | BACKGROUND: Chromogranin-A (CgA) is a secretory protein processed into peptides that regulate angiogenesis and vascular cells activation, migration and proliferation. These processes may influence arterial inflammation and remodelling in Takayasu arteritis (TA). METHODS: Plasma levels of full-length CgA (CgA(439)), CgA fragments lacking the C-terminal region (CgA-FRs) and the N-terminal fragment, CgA(1–76) (vasostatin-1, VS-1) were analysed in 42 patients with TA and 20 healthy age-matched controls. Vascular remodelling was longitudinally assessed by imaging. CgA peptides were related to markers of systemic and local inflammation, disease activity and vascular remodelling. RESULTS: Levels of CgA-FRs and VS-1 were increased in TA. Treatment with proton-pump inhibitors (PPIs) and arterial hypertension partially accounted for CgA levels and high inter-patient variability. CgA(439), CgA-FRs and VS-1 levels did not reflect disease activity or extent. Markers of systemic or local inflammation correlated with higher CgA-FRs and VS-1 in normotensive patients and with higher CgA(439) in hypertensive patients. Treatment with non-biologic anti-rheumatic agents was associated with increased CgA-FRs and a distinctive regulation of CgA processing. Reduced blood levels of anti-angiogenic CgA peptides were associated with vascular remodelling in the groups of patients on PPIs and with arterial hypertension. CONCLUSIONS: The plasma levels of CgA fragments are markedly increased in TA as a consequence of disease- and therapy-related variables. Anti-angiogenic forms of CgA may limit vascular remodelling. Given the effect of the various CgA peptides, it is advisable to limit the therapeutic prescriptions that might influence CgA-derived peptide levels to clearly agreed medical indications until further data become available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1082-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4987982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49879822016-08-18 Chromogranin-A production and fragmentation in patients with Takayasu arteritis Tombetti, Enrico Colombo, Barbara Di Chio, Maria Chiara Sartorelli, Silvia Papa, Maurizio Salerno, Annalaura Bozzolo, Enrica Paola Tombolini, Elisabetta Benedetti, Giulia Godi, Claudia Lanzani, Chiara Rovere-Querini, Patrizia Del Maschio, Alessandro Ambrosi, Alessandro De Cobelli, Francesco Sabbadini, Maria Grazia Baldissera, Elena Corti, Angelo Manfredi, Angelo A. Arthritis Res Ther Research Article BACKGROUND: Chromogranin-A (CgA) is a secretory protein processed into peptides that regulate angiogenesis and vascular cells activation, migration and proliferation. These processes may influence arterial inflammation and remodelling in Takayasu arteritis (TA). METHODS: Plasma levels of full-length CgA (CgA(439)), CgA fragments lacking the C-terminal region (CgA-FRs) and the N-terminal fragment, CgA(1–76) (vasostatin-1, VS-1) were analysed in 42 patients with TA and 20 healthy age-matched controls. Vascular remodelling was longitudinally assessed by imaging. CgA peptides were related to markers of systemic and local inflammation, disease activity and vascular remodelling. RESULTS: Levels of CgA-FRs and VS-1 were increased in TA. Treatment with proton-pump inhibitors (PPIs) and arterial hypertension partially accounted for CgA levels and high inter-patient variability. CgA(439), CgA-FRs and VS-1 levels did not reflect disease activity or extent. Markers of systemic or local inflammation correlated with higher CgA-FRs and VS-1 in normotensive patients and with higher CgA(439) in hypertensive patients. Treatment with non-biologic anti-rheumatic agents was associated with increased CgA-FRs and a distinctive regulation of CgA processing. Reduced blood levels of anti-angiogenic CgA peptides were associated with vascular remodelling in the groups of patients on PPIs and with arterial hypertension. CONCLUSIONS: The plasma levels of CgA fragments are markedly increased in TA as a consequence of disease- and therapy-related variables. Anti-angiogenic forms of CgA may limit vascular remodelling. Given the effect of the various CgA peptides, it is advisable to limit the therapeutic prescriptions that might influence CgA-derived peptide levels to clearly agreed medical indications until further data become available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1082-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-17 2016 /pmc/articles/PMC4987982/ /pubmed/27531191 http://dx.doi.org/10.1186/s13075-016-1082-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Tombetti, Enrico Colombo, Barbara Di Chio, Maria Chiara Sartorelli, Silvia Papa, Maurizio Salerno, Annalaura Bozzolo, Enrica Paola Tombolini, Elisabetta Benedetti, Giulia Godi, Claudia Lanzani, Chiara Rovere-Querini, Patrizia Del Maschio, Alessandro Ambrosi, Alessandro De Cobelli, Francesco Sabbadini, Maria Grazia Baldissera, Elena Corti, Angelo Manfredi, Angelo A. Chromogranin-A production and fragmentation in patients with Takayasu arteritis |
title | Chromogranin-A production and fragmentation in patients with Takayasu arteritis |
title_full | Chromogranin-A production and fragmentation in patients with Takayasu arteritis |
title_fullStr | Chromogranin-A production and fragmentation in patients with Takayasu arteritis |
title_full_unstemmed | Chromogranin-A production and fragmentation in patients with Takayasu arteritis |
title_short | Chromogranin-A production and fragmentation in patients with Takayasu arteritis |
title_sort | chromogranin-a production and fragmentation in patients with takayasu arteritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987982/ https://www.ncbi.nlm.nih.gov/pubmed/27531191 http://dx.doi.org/10.1186/s13075-016-1082-2 |
work_keys_str_mv | AT tombettienrico chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT colombobarbara chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT dichiomariachiara chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT sartorellisilvia chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT papamaurizio chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT salernoannalaura chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT bozzoloenricapaola chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT tombolinielisabetta chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT benedettigiulia chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT godiclaudia chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT lanzanichiara chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT roverequerinipatrizia chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT delmaschioalessandro chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT ambrosialessandro chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT decobellifrancesco chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT sabbadinimariagrazia chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT baldisseraelena chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT cortiangelo chromograninaproductionandfragmentationinpatientswithtakayasuarteritis AT manfrediangeloa chromograninaproductionandfragmentationinpatientswithtakayasuarteritis |